ADAG

AdageneA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.25

+84.4% vs current

Most likely

Base case

45%

Probability

Target price

$4.10

+20.9% vs current

B-

Bear case

30%

Probability

Target price

$2.40

-29.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Sentiment is cautious rather than outright bullish. The April 2026 update improved clinical credibility and the balance sheet is less fragile than before, but deterministic evidence strength in the packet is effectively zero and the forward thesis still depends on year-end 2026 checkpoints and a 1H 2027 randomized readout. That keeps ADAG in a low-conviction monitoring bucket despite a more defendable runway and multiple partner-backed combination shots on goal [#PR-2026-04-01] [#PR-2026-04-02-data] [#PR-2026-04-02-offer].

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystPost-offering balance-sheet reset versus dilution overhangHigh impact

Adagene priced an underwritten public offering of 18,666,000 ADSs at $3.75 for expected gross proceeds of about $70.0 million, with the deal expected to close on April 6, 2026; near-term trading likely reflects a tug-of-war between improved funding visibility and dilution/deal-price anchoring [#PR-2026-04-02-offer] [#6K-2026-04-02-offer].

2026-12-31event2026 additional muzastotug combination data and new-study startsHigh impact

Management reiterated 2026 objectives that include preliminary neoadjuvant data, initial fruquintinib-combination data, Roche triplet-study results, and additional collaboration/licensing progress; separately, the Incyte collaboration says the INCA33890 plus muzastotug Phase 1 study is expected to begin in 2026 [#PR-2026-01-23] [#PR-2026-04-01] [#PR-2026-04-02-incyte].

2027-06-30catalystRandomized Phase 2 dose-optimization readout for muzastotug in MSS CRCHigh impact

The company has already started the randomized Phase 2 study, said enrollment is ongoing and results are expected in 1H 2027, with the trial intended to support dose selection for a potential registration path; this remains the cleanest value-defining catalyst because April 2026 updated Phase 1b/2 data still come from small, non-randomized cohorts despite stronger 20 mg/kg activity [#PR-2025-10-31] [#PR-2026-04-01] [#PR-2026-04-02-data].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology